234 related articles for article (PubMed ID: 16021881)
41. A prospective study of efficacy and safety of once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patients.
Ananworanich J; Hill A; Siangphoe U; Ruxrungtham K; Prasithsirikul W; Chetchotisakd P; Kiertiburanakul S; Munsakul W; Raksakulkarn P; Tansuphasawadikul S; Nuesch R; Cooper DA; Hirschel B;
Antivir Ther; 2005; 10(6):761-7. PubMed ID: 16218176
[TBL] [Abstract][Full Text] [Related]
42. The V118I mutation as a marker of advanced HIV infection and disease progression.
Zaccarelli M; Tozzi V; Lorenzini P; Forbici F; Narciso P; Ceccherini-Silberstein F; Trotta MP; Bertoli A; Liuzzi G; Marconi P; Mosti S; Perno CF; Antinori A
Antivir Ther; 2007; 12(2):163-8. PubMed ID: 17503658
[TBL] [Abstract][Full Text] [Related]
43. Hydroxyurea in HIV therapy.
HIV Hotline; 1998 Mar; 8(1):5-7. PubMed ID: 11365359
[TBL] [Abstract][Full Text] [Related]
44. Hydroxyurea in the treatment of HIV infection: clinical efficacy and safety concerns.
Lisziewicz J; Foli A; Wainberg M; Lori F
Drug Saf; 2003; 26(9):605-24. PubMed ID: 12814330
[TBL] [Abstract][Full Text] [Related]
45. Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs.
Moore RD; Keruly JC; Chaisson RE
AIDS; 2001 Mar; 15(5):617-20. PubMed ID: 11316999
[TBL] [Abstract][Full Text] [Related]
46. Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea.
Moore RD; Wong WM; Keruly JC; McArthur JC
AIDS; 2000 Feb; 14(3):273-8. PubMed ID: 10716503
[TBL] [Abstract][Full Text] [Related]
47. The role of didanosine in the management of HIV-1 infection.
Gazzard BG; Moyle GJ
Antivir Ther; 1997 Jul; 2(3):135-47. PubMed ID: 11322269
[TBL] [Abstract][Full Text] [Related]
48. HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
Sungkanuparph S; Apiwattanakul N; Thitithanyanont A; Chantratita W; Sirinavin S
Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):83-8. PubMed ID: 19323038
[TBL] [Abstract][Full Text] [Related]
49. Long-distance interactive expert advice in highly treatment-experienced HIV-infected patients.
Llibre JM; Domingo P; del Pozo MA; Miralles C; Galindo MJ; Viciana I; Moreno S; Schapiro JM; Clotet B
J Antimicrob Chemother; 2008 Jan; 61(1):206-9. PubMed ID: 17999972
[TBL] [Abstract][Full Text] [Related]
50. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.
Jones R; Sawleshwarkar S; Michailidis C; Jackson A; Mandalia S; Stebbing J; Bower M; Nelson M; Gazzard BG; Moyle GJ
HIV Med; 2005 Nov; 6(6):396-402. PubMed ID: 16268821
[TBL] [Abstract][Full Text] [Related]
51. HIV RNA viral load and CD4+ T-cell counts in HIV-infected pregnant women with and without treatment discontinuation in early pregnancy.
Tamburrini E; Ravizza M; Floridia M; Tibaldi C; Alberico S; Anzidei G; Maccabruni A; Meloni A; Antoni AD; Mori F; Dalzero S; Conservan V; Pinnetti C; Ferrazzi E;
Antivir Ther; 2008; 13(4):519-27. PubMed ID: 18672530
[TBL] [Abstract][Full Text] [Related]
52. CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.
Torti C; Lapadula G; Barreiro P; Soriano V; Mandalia S; De Silvestri A; Suter F; Maggiolo F; Antinori A; Antonucci F; Maserati R; El Hamad I; Pierotti P; Sighinolfi L; Migliorino G; Ladisa N; Carosi G;
J Antimicrob Chemother; 2007 Jun; 59(6):1141-7. PubMed ID: 17434879
[TBL] [Abstract][Full Text] [Related]
53. An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults.
Bartlett JA; Fath MJ; Demasi R; Hermes A; Quinn J; Mondou E; Rousseau F
AIDS; 2006 Oct; 20(16):2051-64. PubMed ID: 17053351
[TBL] [Abstract][Full Text] [Related]
54. Hydroxyurea and didanosine is a more potent combination than hydroxyurea and zidovudine.
Foli A; Lori F; Maserati R; Tinelli C; Minoli L; Lisziewicz J
Antivir Ther; 1997 Jan; 2(1):31-8. PubMed ID: 11322264
[TBL] [Abstract][Full Text] [Related]
55. Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients.
Antinori A; Trotta MP; Nasta P; Bini T; Bonora S; Castagna A; Zaccarelli M; Quirino T; Landonio S; Merli S; Tozzi V; Di Perri G; Andreoni M; Perno CF; Carosi G
Antivir Ther; 2006; 11(2):233-43. PubMed ID: 16640104
[TBL] [Abstract][Full Text] [Related]
56. New data intensifies interest in hydroxyurea.
Santiago LG
GMHC Treat Issues; 1995 Sep; 9(9):1, 3-4. PubMed ID: 11362902
[TBL] [Abstract][Full Text] [Related]
57. Hydroxyurea - new observations.
Proj Inf Perspect; 1998 Apr; (24):15-7. PubMed ID: 11365714
[TBL] [Abstract][Full Text] [Related]
58. Pilot study of hydroxyurea in human immunodeficiency virus-infected children receiving didanosine and/or stavudine.
Kline MW; Calles NR; Simon C; Schwarzwald H
Pediatr Infect Dis J; 2000 Nov; 19(11):1083-6. PubMed ID: 11099091
[TBL] [Abstract][Full Text] [Related]
59. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.
Soria A; Porten K; Fampou-Toundji JC; Galli L; Mougnutou R; Buard V; Kfutwah A; Vessière A; Rousset D; Teck R; Calmy A; Ciaffi L; Lazzarin A; Gianotti N
Antivir Ther; 2009; 14(3):339-47. PubMed ID: 19474468
[TBL] [Abstract][Full Text] [Related]
60. Long-term assessment of nevirapine-containing highly active antiretroviral therapy in antiretroviral-naive HIV-infected patients: 3-year follow-up of the VIRGO study.
Reliquet V; Allavena C; François-Brunet C; Perré P; Bellein V; Garré M; May T; Souala F; Besnier JM; Raffi F
HIV Med; 2006 Oct; 7(7):431-6. PubMed ID: 16925728
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]